Cabometyx cabozantinib regulatory update

The European Commission approved Cabometyx cabozantinib tablets from Exelixis as monotherapy to treat adults with advanced renal cell carcinoma (RCC) who have been previously treated with a VEGF inhibitor. The approval triggered a $60 million milestone payment to Exelixis from Ipsen under a February deal granting Ipsen exclusive rights to the product outside of the U.S., Canada and Japan (see BioCentury, March 7). ...